Pub Date : 2022-01-01DOI: 10.5336/cardiosci.2022-90615
C. Soliman, S. Agwa, S. Fathy, M. Emam, Ahmed M. Elshazly, D. Ibrahim
ABS TRACT Objective: Non-coding RNAs are the RNAs with no pro- tein coding function, long non-coding RNAs (LncRNAs) are the non-co-ding RNAs with more than 200 nucleotides. During the journey of discovering novel biomarkers for diagnosis of myocardial infarction (MI), the principle of studying the LncRNA as a potential would be al- ways attractive, as it needs easy sample collection, has high detection sensitivity and high myocardial tissue specificity. Our main objective was to investigate the potential of LINC01538 as a novel diagnostic biomarker for MI. Material and Methods: Quantitative real-time poly- merase chain reaction (RT-qPCR) was used to assess the expression of the serum LINC01538 in 50 ST Elevation MI (STEMI) patients and 48 controls. Results: The study showed a significant increase in serum level expression of LINC01538 in MI patients compared to controls [12 (6.6- 21.8) vs. 0.07 (0.01-0.2), p<0.001]. LINC01538 expression level in MI group was positively correlated with creatine kinase MB and high sen- sitive cardiac troponin I (hs-cTnI) (r=0.39, p=0.006 and r=0.22, p=0.007, respectively). Hs-cTnI found to have diagnostic value for MI with an area under curve (AUC) 0.917 [95% confidence interval (CI): 0.855-0.979, p<0.001] at an optimal cutoff point of 1.45 ng/L, 90% sensitivity and 91% specificity. However, LINC01538 showed the highest diagnostic value with an AUC 0.980 (95% CI: 0.942- 1, p<0.001) at an op- timal cut-off point of 1.76, 100% sensitivity and 98% specificity. Conclusion: Our findings have, for the first time, demonstrated that cir- culating LINC01538 are highly expressed in patients with MI, functioning as potential novel biomarker for diagnosis.
{"title":"Circulating Long Intergenic Non-Coding RNA LINC01538 as Potential Novel Biomarker for Acute Myocardial Infarction: Prospective Cohort Study","authors":"C. Soliman, S. Agwa, S. Fathy, M. Emam, Ahmed M. Elshazly, D. Ibrahim","doi":"10.5336/cardiosci.2022-90615","DOIUrl":"https://doi.org/10.5336/cardiosci.2022-90615","url":null,"abstract":"ABS TRACT Objective: Non-coding RNAs are the RNAs with no pro- tein coding function, long non-coding RNAs (LncRNAs) are the non-co-ding RNAs with more than 200 nucleotides. During the journey of discovering novel biomarkers for diagnosis of myocardial infarction (MI), the principle of studying the LncRNA as a potential would be al- ways attractive, as it needs easy sample collection, has high detection sensitivity and high myocardial tissue specificity. Our main objective was to investigate the potential of LINC01538 as a novel diagnostic biomarker for MI. Material and Methods: Quantitative real-time poly- merase chain reaction (RT-qPCR) was used to assess the expression of the serum LINC01538 in 50 ST Elevation MI (STEMI) patients and 48 controls. Results: The study showed a significant increase in serum level expression of LINC01538 in MI patients compared to controls [12 (6.6- 21.8) vs. 0.07 (0.01-0.2), p<0.001]. LINC01538 expression level in MI group was positively correlated with creatine kinase MB and high sen- sitive cardiac troponin I (hs-cTnI) (r=0.39, p=0.006 and r=0.22, p=0.007, respectively). Hs-cTnI found to have diagnostic value for MI with an area under curve (AUC) 0.917 [95% confidence interval (CI): 0.855-0.979, p<0.001] at an optimal cutoff point of 1.45 ng/L, 90% sensitivity and 91% specificity. However, LINC01538 showed the highest diagnostic value with an AUC 0.980 (95% CI: 0.942- 1, p<0.001) at an op- timal cut-off point of 1.76, 100% sensitivity and 98% specificity. Conclusion: Our findings have, for the first time, demonstrated that cir- culating LINC01538 are highly expressed in patients with MI, functioning as potential novel biomarker for diagnosis.","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76375726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.5336/cardiosci.2022-92530
M. Kış, Tuncay Güzel
{"title":"Hemoglobin A1c is a Predictor of Poor Collateral Development in Non-Diabetic Patients with Coronary Chronic Total Occlusion: Retrospective Clinical Trial","authors":"M. Kış, Tuncay Güzel","doi":"10.5336/cardiosci.2022-92530","DOIUrl":"https://doi.org/10.5336/cardiosci.2022-92530","url":null,"abstract":"","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90936541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.5336/cardiosci.2020-78435
T. Karabağ, F. Mutlu, S. Efe
{"title":"Fibrosis-4 Index for Prediction of the Severity of Acute Pulmary Embolism: Cross-sectional Research","authors":"T. Karabağ, F. Mutlu, S. Efe","doi":"10.5336/cardiosci.2020-78435","DOIUrl":"https://doi.org/10.5336/cardiosci.2020-78435","url":null,"abstract":"","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86550560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.5336/cardiosci.2021-84366
Aysun Erdem Yaman, U. S. Ceylan
{"title":"The Effect of Vitamin D Deficiency on the Risk and Time of Stent Restenosis After Percutaneous Coronary Angioplasty: Case-Control Study","authors":"Aysun Erdem Yaman, U. S. Ceylan","doi":"10.5336/cardiosci.2021-84366","DOIUrl":"https://doi.org/10.5336/cardiosci.2021-84366","url":null,"abstract":"","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75078368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.5336/CARDIOSCI.2020-80082
I. Cerik, Hatun Öztürk Çerik, A. Dogan, S. Dereli, O. Bektaş, Y. Kaya
Objective: The Coronavirus disease-2019 (COVID-19) pandemic has caused the death of many people worldwide. Treatment protocol had to be developed as soon as possible so drug combinations, whose reliability has not been fully disclosed, have started to be used. In this study, we aimed to evaluate the effect of azithromycin (AZT), hydroxychloroquine (HCQ), and favipiravir (FVR) combination on the corrected QT (QTc) interval. Material and Methods: Eighty-four consecutive COVID 19 patients were enrolled in the study. All patients received AZT and HCQ, however, FVR was added to the combination in 32 patients with severe pneumonia at the beginning. ECG characteristics of all patients before treatment and on the fifth day of treatment were compared. Results: There was no significant difference between the HCQ+AZT group (n=52) and HCQ+AZT+FVR groups (n=32) in terms of baseline clinical characteristics. QTc interval significantly prolonged on the fifth day of treatment in the HCQ+AZT group (413,75±30,13;440,27±36,11 p<0.001) and in the HCQ+AZT+FVR group (426,65±32,83;468,22±42,13 p<0.001). When both groups were compared in terms of ΔQTc, a significant increase was observed in the HCQ+AZT+FVR group compared to the HCQ+AZT group (40(-14/175), 23(-28/213) respectively, p=0.042). In seven of the patients, QTc> 500 ms was detected after the treatment, four patients in the HCQ+AZT+FVR group and three patients in the HCQ+AZT group. Conclusion: We observed that FVR caused more prolongation in the QTc interval when used with the combination of HCQ+AZT. We recommend that patients who receive this treatment be monitored more closely for QTc.
{"title":"Impact of Adding Favipiravir to Hydroxychloroquine and Azithromycin Treatment on QTc Interval in COVID-19","authors":"I. Cerik, Hatun Öztürk Çerik, A. Dogan, S. Dereli, O. Bektaş, Y. Kaya","doi":"10.5336/CARDIOSCI.2020-80082","DOIUrl":"https://doi.org/10.5336/CARDIOSCI.2020-80082","url":null,"abstract":"Objective: The Coronavirus disease-2019 (COVID-19) pandemic has caused the death of many people worldwide. Treatment protocol had to be developed as soon as possible so drug combinations, whose reliability has not been fully disclosed, have started to be used. In this study, we aimed to evaluate the effect of azithromycin (AZT), hydroxychloroquine (HCQ), and favipiravir (FVR) combination on the corrected QT (QTc) interval. Material and Methods: Eighty-four consecutive COVID 19 patients were enrolled in the study. All patients received AZT and HCQ, however, FVR was added to the combination in 32 patients with severe pneumonia at the beginning. ECG characteristics of all patients before treatment and on the fifth day of treatment were compared. Results: There was no significant difference between the HCQ+AZT group (n=52) and HCQ+AZT+FVR groups (n=32) in terms of baseline clinical characteristics. QTc interval significantly prolonged on the fifth day of treatment in the HCQ+AZT group (413,75±30,13;440,27±36,11 p<0.001) and in the HCQ+AZT+FVR group (426,65±32,83;468,22±42,13 p<0.001). When both groups were compared in terms of ΔQTc, a significant increase was observed in the HCQ+AZT+FVR group compared to the HCQ+AZT group (40(-14/175), 23(-28/213) respectively, p=0.042). In seven of the patients, QTc> 500 ms was detected after the treatment, four patients in the HCQ+AZT+FVR group and three patients in the HCQ+AZT group. Conclusion: We observed that FVR caused more prolongation in the QTc interval when used with the combination of HCQ+AZT. We recommend that patients who receive this treatment be monitored more closely for QTc.","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74082104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.5336/cardiosci.2021-84307
Aleksey Michailovich Chaulin
{"title":"Diagnostic Considerations and Analytical Characteristics of Methods for the Determination of Cardiac Troponins: Traditional Review","authors":"Aleksey Michailovich Chaulin","doi":"10.5336/cardiosci.2021-84307","DOIUrl":"https://doi.org/10.5336/cardiosci.2021-84307","url":null,"abstract":"","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80031651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.5336/cardiosci.2021-82604
H. S. Başbuğ, V. Kızılgöz
{"title":"Femoral Artery Stenosis Due to Perivascular Mass: Endovascular Treatment of an Intraoperatively Detected Condition","authors":"H. S. Başbuğ, V. Kızılgöz","doi":"10.5336/cardiosci.2021-82604","DOIUrl":"https://doi.org/10.5336/cardiosci.2021-82604","url":null,"abstract":"","PeriodicalId":39118,"journal":{"name":"Turkiye Klinikleri Cardiovascular Sciences","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77396580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：